NCT07281495Active, not recruitingPhase 2
Taldefgrobep Alfa in Adults With Overweight and Obesity
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With Open-Label Extension to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Taldefgrobep Alfa in Adults Living With Overweight and Obesity
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 4 Dec 2025
- Start date
- 24 Nov 2025
- Primary completion date
- Sept 2026
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Diseases
- Obesity
- NCT number
- NCT07281495
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 150
- From 24 Nov 2025 to the primary completion date, Sept 2026
- 20 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- History of diabetes, including individuals with a HbA1c of ≥ 6.5% at Screening
Other
- Non-ambulatory participants, defined as unable to take at least 10 steps independently.
- Females currently pregnant or breastfeeding, or who intend to become pregnant or to breastfeed.
- Participation in another investigational clinical trial while participating in this clinical trial
Who the study is looking for
- a. BMI \> 30 kg/m2 and BMI \< 42 kg/m2, OR b. BMI ≥ 27 kg/m2 and BMI \<30 kg/m2 with at least one weight-related co-morbidity
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
- Stable body weight and stable physical activity within 3 months prior to screening per participant self-report.
- All participants must adhere to protocol contraception requirements
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (20)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.